Evidence map›Paper›PMID 29498789›Full record

ArticleCancer science2018

Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143.

Yukihiro Akao, Minami Kumazaki, Haruka Shinohara, Nobuhiko Sugito, Yuki Kuranaga, Takuya Tsujino, Yuki Yoshikawa, Yukio Kitade

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Metastasis Inhibition.International journal of molecular sciences · 2023
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yukihiro AkaoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.ORCID http://orcid.org/0000-0001-8902-5367
Minami KumazakiUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Haruka ShinoharaUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Nobuhiko SugitoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Yuki KuranagaUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Takuya TsujinoUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Yuki YoshikawaUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Yukio KitadeUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.
Gifu University · JPAichi Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite considerable research on K-Ras inhibitors, none had been established until now. We synthesized nuclease-resistant synthetic miR-143 (miR-143#12), which strongly silenced K-Ras, its effector signal molecules AKT and ERK, and the K-Ras activator Sos1. We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations. Cell growth was markedly suppressed in a concentration-dependent manner by miR-143#12 (IC

Indexed as

AnimalsBenzimidazolesBenzothiazolesCell Line, TumorCell ProliferationCell SurvivalColonic NeoplasmsDrug SynergismFlavonoidsHT29 CellsHumansMiceMicroRNAsMutationNeoplasm TransplantationProtein Kinase Inhibitors2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one5233705 compoundBenzimidazolesBenzothiazolesFlavonoidsKRAS protein, humanMicroRNAsMIRN143 microRNA, humanProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)epidermal growth factor receptorK-RasmiR-143Ras inhibitorSos1

Identifiers

PMID29498789
PMCPMC5980131
OpenAlexW2794338339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.